Story
Sionna Therapeutics to Cut 46% of Staff, Pivots CF Drug Strategy After Trial Setback
Summary
Sionna Therapeutics announced a major restructuring and a new clinical focus after its SION-719 drug failed to meet its primary endpoint, causing shares to fall in after-hours trading.
Sionna Therapeutics Inc. (NASDAQ:SION) shares fell 3% in after-hours trading Monday after the company announced a significant strategic shift, including a 46% reduction in its workforce. The clinical-stage biopharmaceutical firm is pivoting its development focus to a new cystic fibrosis (CF) drug combination following disappointing clinical trial results for a prior candidate.
Strategic Restructuring
Sionna will now advance SION-451 + SION-2222, a proprietary dual-drug combination, into a Phase 2a trial. The company stated this new trial, named AscenSION CF, is expected to begin in the first quarter of 2027. The open-label study will evaluate the combination's effect on sweat chloride levels, safety, and pharmacokinetics in adults with CF who are homozygous for the F508del mutation.
To support this new focus, Sionna's board approved cost-saving measures, including the staff reduction. The company anticipates incurring approximately $6.4 million in restructuring charges. These changes are expected to extend its cash runway into the second half of 2029, based on its second-quarter 2026 cash position of approximately $268.3 million.
Rationale for the Pivot
AdThe decision follows a review of data from the PreciSION CF Phase 2a trial for its previous drug candidate, SION-719. According to the company, the trial, which tested SION-719 as an add-on to the standard-of-care treatment Trikafta, failed to achieve its key activity endpoint.
While a post hoc analysis showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L in a subset of participants, Sionna identified several issues that may have compromised the overall results:
- Drug exposure outliers in three participants, which were consistent with non-adherence to the treatment regimen.
- Lower exposures to Trikafta's components during the SION-719 treatment periods.
- Potential interactions between SION-719 and another drug component that may have blunted the therapeutic benefits.
Read next
More on Stocks
Record Diesel Prices Squeeze US Farmers, Threaten Higher Food Inflation
US farmers are facing record-high diesel costs during the crucial harvest season, a development that is squeezing profit margins and expected to push consumer food prices higher across the supply chain.
US Draft Rules to Permit Most Pharma Licensing Deals with China, Sources Say
The U.S. Treasury Department is reportedly drafting rules that would allow American pharmaceutical companies to continue most licensing deals with Chinese firms, sources say, avoiding broad restrictions sought by some lawmakers over national security concerns.
Century Aluminum's $4B Oklahoma Smelter Project Stalled by Local Opposition
A proposed $4 billion aluminum smelter in Oklahoma, backed by Century Aluminum and Emirates Global Aluminium, faces a prolonged local moratorium and a public referendum, creating significant uncertainty despite a key political victory for its supporters.
BofA Upgrades Equinor to 'Buy' on Bullish European Gas Price Forecast
BofA Securities raised its rating on Equinor to "Buy" from "Neutral," citing an improved outlook for European gas prices that is expected to significantly boost the energy company's cash flow. The bank also increased its price target to 465 Norwegian kroner.